GoodRx Holdings, Inc.

As of March 31, 2026 , we had cash and cash equivalents of $235.7 million and total outstanding debt of $493.8 million .

SEC original ↗GoodRx Holdings, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026

Our capital allocation priorities are investing for profitable growth, paying down debt, buying back shares, and M A that aligns with our strategic priorities.

SEC original ↗GoodRx Holdings, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026

Exhibit 99.1 Share Repurchases During the first quarter of 2026 , we repurchased 5.5 million shares of Class A common stock for an aggregate of $12.6 million .

SEC original ↗GoodRx Holdings, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026

As of March 31, 2026 , we had $60.2 million of unused authorized share repurchase capacity under our $450.0 million share repurchase program, which does not have an expiration date.

SEC original ↗GoodRx Holdings, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026

We define Adjusted EBITDA for a particular period as net income or loss before interest, taxes, depreciation and amortization, and as further adjusted for, as applicable for the periods presented, acquisition related expenses, stock-based compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing related expenses, loss on operating lease assets, restructuring related expenses, legal settlement expenses, gain on sale of business, and other income or expense, net.

SEC original ↗GoodRx Holdings, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026

We define Adjusted Net Income for a particular period as net income or loss adjusted for, as applicable for the periods presented, amortization of intangibles related to acquisitions and restructuring activities, acquisition related expenses, stock- based compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing related expenses, loss on operating lease assets, restructuring related expenses, legal settlement expenses, gain on sale of business, other income or expense, net, and as further adjusted for estimated income tax on such adjusted items.

SEC original ↗GoodRx Holdings, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026

Net income of $1.2 million Net income margin of 0.6% Adjusted Net Income 1 of $23.0 million Adjusted Net Income Margin 1 of 11.9% Adjusted EBITDA 1 of $58.3 million Adjusted EBITDA Margin 1 of 30.0% Net cash provided by operating activities of $11.8 million We delivered a strong start to the year, with continued momentum across our strategic growth priorities, said Wendy Barnes, President and Chief Executive Officer of GoodRx.

SEC original ↗GoodRx Holdings, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026

Our results demonstrate that the strategy we laid out last quarter is working and that we are building a sustainable value proposition.

SEC original ↗GoodRx Holdings, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026

We are focused on a disciplined approach to capital allocation, centered on furthering our mission and creating stockholder value.

SEC original ↗GoodRx Holdings, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026

Our capital allocation priorities are investing for profitable growth, paying down debt, buying back shares, and M A that aligns with our strategic priorities.

SEC original ↗GoodRx Holdings, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026

These capital allocation priorities support our long-term growth strategy while also providing flexibility to navigate near-term challenges.

SEC original ↗GoodRx Holdings, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026

These capital allocation priorities support our long-term growth strategy while also providing flexibility to navigate near-term challenges.

SEC original ↗GoodRx Holdings, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026

We have not reconciled our Adjusted EBITDA guidance to GAAP net income or loss because we do not provide guidance for such GAAP measure due to the uncertainty and potential variability of stock-based compensation expense, acquired intangible assets and related amortization and income taxes, which are reconciling items between Adjusted EBITDA and the most directly comparable GAAP measure.

SEC original ↗GoodRx Holdings, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026

All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our future results of operations and financial position, industry and business trends, including uncertainty in the macro environment, the impact of trends impacting retail pharmacies on our future financial results, the potential impact of the new government sponsored direct-to-consumer platform called TrumpRx.

SEC original ↗GoodRx Holdings, Inc. — Earnings release (8-K exhibit)EX-99May 6, 2026

Legal Proceedings 25 Item 1A.

SEC original ↗GoodRx Holdings, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Legal Contingencies Consumer privacy class action - Between February 2, 2023, and March 30, 2023, five individual plaintiffs filed five separate putative class action lawsuits against Google, Meta, Criteo and us, alleging generally that we have not adequately protected consumer privacy and that we communicated consumer information to third parties, including the three co- defendants.

SEC original ↗GoodRx Holdings, Inc. — 10-Q Quarterly report10-QAug 5, 2026

In response to the proposed settlement in the SDFL Class Action Matter, plaintiffs in the NDCA Class Action Matter filed (i) on November 1, 2023, a motion in the NDCA for an order to require us to cease litigation of, or alternatively file a motion to stay in, the SDFL Class Action Matter and enjoin us from seeking settlement with counsel other than plaintiffs counsel in the NDCA Class Action Matter; and (ii) on November 2, 2023, a motion in the SDFL for that court to allow them to intervene and appear in the SDFL action, transfer the SDFL Class Action Matter to the NDCA and reconsider and deny its preliminary approval of the proposed settlement.

SEC original ↗GoodRx Holdings, Inc. — 10-Q Quarterly report10-QAug 5, 2026